FCA
MNPR icon

FinTrust Capital Advisors’s Monopar Therapeutics MNPR Stock Holding History

FinTrust Capital Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$1K – 1275
2022
Q1 		$1K Hold
100
– – ﹤0.01% 1179
2021
Q4 		$2K Buy
+100
New +$2.22K ﹤0.01% 1107

Other funds holding MNPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

FinTrust Capital Advisors's MNPR Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Monopar Therapeutics (MNPR) in Q2 2022, closing a stake of 100 shares — an estimated $1K sold.

FinTrust Capital Advisors first reported a position in MNPR in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 13 funds tracked by Wall St. Rank hold MNPR as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Monopar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 100 Monopar Therapeutics shares in Q2 2022, an estimated $1K.
  • FinTrust Capital Advisors first reported a position in Monopar Therapeutics in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's Monopar Therapeutics position peaked at $2K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.